Aln-Ttrsc04
Transthyretin-Mediated Amyloidosis
Alnylam PharmaceuticalsPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Transthyretin-Mediated Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eplontersen AstraZeneca | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →